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Vaccine
Efficacy &
Effectiveness
A Statistician's Perspective
Dr. Jyotishka Datta, Virginia Tech, Statistics.

"The inspiration of the
camel image is that it
represents the
dedication of the world
to bring vaccines to
everyone."
- Halloran et al. (2009),
Design & Analysis of
Vaccine Studies

On May 10, 2021

November 20, 2020, New York Times, Carl Zimmer

Efficacy

• Vaccine efficacy (and vaccine effectiveness), VE, are
generally estimated as one minus some measure of
relative risk, RR, in the vaccinated group compared to
the unvaccinated group:
VE = 1 - RR
• The groups being compared could be composed of
individuals or of populations or communities.

Pfizer

GROUP

GROUP
SIZE

NUMBER
INFECTED

INFECTION
RISK

US POP.

Placebo

21,830

162

162/21830=
0.74%

2.5 million

Vaccine

21830

8

8/21830 =
0.04%

131,000

• Pfizer recruited 43,661
volunteers and waited
for 170 people to come
down with symptoms of
Covid-19 and get a
positive test.
• Out of these 170, 162
were from the 'placebo’
group and just
eight were from the
‘vaccine’ group.
• (Groups are randomly
allocated)

• Recall, VE = 1 – RR = 1 - (risk for vaccine
group)/(risk for placebo)
• Placebo group's infection risk: 0.74%
• Vaccine group's infection risk: 0.04%

Efficacy

• VE = 1 – 0.04/0.74 = (0.74 - 0.04)/0.74 = 0.95
• This captures the difference in impact by scaling
the percentage point difference in risks by the
original infection risk.
• What factors influence efficacy? How do we
control for age, gender, ethnicity, co-morbidities
etc.?

Piero Olliaro, “What Does 95% COVID-19 Vaccine Efficacy Really Mean?”

Quote from
the letter

• "The mRNA-based Pfizer and Moderna vaccines
were shown to have 94–95% efficacy in
preventing symptomatic COVID-19, calculated as
100 × (1 minus the attack rate with vaccine divided
by the attack rate with placebo)."
• "It means that in a population such as the one
enrolled in the trials, with a cumulated COVID-19
attack rate over a period of 3 months of about 1%
without a vaccine, we would expect roughly 0·05%
of vaccinated people would get diseased."
• "It does not mean that 95% of people are
protected from disease with the vaccine—a general
misconception of vaccine protection also found in a
Lancet Infectious Diseases Editorial."

Piero Olliaro, “What Does 95% COVID-19 Vaccine Efficacy Really Mean?”
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Characterizing
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Effectivenss vs
Efficacy

Digging
deeper

History of vaccines

This Photo by Unknown author is licensed under CC BY-SA-NC.

History of
vaccines
• The word vaccine was derived from Latin
word 'vacca' for cow*, when English
physician Edward Jenner introduced
cowpox-based vaccine against smallpox
in 1796.
• Apparently, that story was probably not
correct. As an NEJM article showed in
2017 (by analyzing historical containers),
the vaccine used to prevent small-pox
was horse-pox, and maybe ... we should
have called it 'equusine'.

Historical
Perspectives
"The fundamental logic
behind today’s vaccine
trials was worked out by
statisticians over a century
ago."

Through the centuries
• After nearly a 100-years of hiatus, at the end of the 19th century, inoculations against

•
•
•
•

cholera, typhoid, plague (caused by bacteria) and rabies (caused by a virus) were
developed
By the early 20th century, legendary statisticians Karl Pearson, Major
Greenwood, and Udny Yule were deeply engaged in discussions
of assessing these vaccines in the field.
1920's: Pertussis, diptheria, tetanus, and bacille Calmette-Gu´erin against
tuberculosis
1930's: yellow fever, influenza, and rickettsia vaccines
Post-war: polio, measles, mumps, rubella, varicella, and adenovirus.

Greenwood &
Yule (1915)
paper
• Famous opening line:
• “Hardly any subjects within
the range of preventive medic
ine is of more immediate
importance than the methods
of prophylaxis which ought to
be adopted with respect to
typhoid fever and cholera”

Why two
tables?
• Whether to “class as
inoculated those who were so
at the date of the last return
made or only those
actually inoculated at the
time of arrival on the foreign
station” ?

Why two
tables?
• In the former case, there
may be an exaggeration of
the “number of men who
were inoculated during the
whole exposure to infection,”
• In the latter case, one
would underestimate it
“because many inoculations
were done shortly after
arrival”
• How to adjust for this effect?
• Pre-date formal 'randomized
studies'

Poliomyelitis vaccine
• In 1954, an enormous field study - total of
1,829,916 children participated in the
nationwide study.
• Observed control study.
• "to administer vaccine to children in the
second grade of school; the
corresponding first and third graders
would not be inoculated, but would be
kept under observation for the
occurrence of poliomyelitis in comparison
with the inoculated second graders”
• not a blinded study + effect of age might
lead to bias !!

Poliomyelitis vaccine
• The plan was changed in mid-stream. In the second
plan, called the Placebo Control Study, “children of
the first, second, and third grades would be
combined. One half would receive vaccine; the other
matching half, serving as strict controls, would
receive a solution of similar appearance (placebo)”
• Despite flaws, this vaccine had 72% efficacy.
• The Salk (injected) and Sabin (oral) polio
vaccines have been 'transformative' - three polio virus
strains has been eliminated in most countries of the
world.

Randomized
Controlled
Trials

Randomized
clinical trial

• Double-blinded randomized controlled trial (RCT)
• Group of participants placed either in a control
group or experimental, completely at random,
people going in are not aware of which group
they're in, neither the researchers.
• The idea is that the experimental & control groups
would be similar in terms of potential factors,
such as, age, gender, ethnicity etc.
• Keep in mind: There could be issues of ethics
("necessary to know if the vaccine was better than
what was available at the time")
• Other types of biases, too.

"Efficacy was consistent across age, gender, race and
ethnicity demographics; observed efficacy in adults
over 65 years of age was over 94%"

Details from
Pfizer's
website

"The Phase 3 clinical trial of BNT162b2 began on July
27 and has enrolled 43,661 participants to date,
41,135 of whom have received a second dose of the
vaccine candidate as of November 13, 2020".
"Approximately 42% of global participants and 30%
of U.S. participants have racially and ethnically
diverse backgrounds, and 41% of global and 45% of
U.S. participants are 56-85 years of age."

Efficacy depends on a lot of things!
• Where? J&J conducted trials in US, Latin America,
South Africa.
• Overall efficacy lower than US-specific efficacy.
• In South Africa, trials took place after a new
variants B.1.351 emerged, affecting the efficacy.
• But it didn't make it useless (SA efficacy ~ 64%)
• Also, when do we look at outcomes? J&J has 85%
efficacy against severe cases.

Direct & Indirect effects
• Safe & effective vaccine strategy
offers both
(1) direct protection (high-risk) and
(2) indirect (reduce transmission for
those in contact with high-risk).

Marc Lipsitch and Natalie E. Dean, “Understanding COVID-19 Vaccine
Efficacy”, Science.

Strategy

• Elderly & people with comorbidities are at
greatest risk - age structured mathematical
models.
• Need to know well the vaccine works in
which groups.
• Phase 3 trials provide insights about
individual level efficacy & safety.
• However, assessing subgroup-specific
efficacy is often challenging, and needs
more work.
• For example, blinded follow-up studies can
provide evidence on long-term safety,
efficacy & age-specific effects.

Uncertainty

Uncertainty

• The efficacy numbers
you see (e.g., 95%) are
point estimates.
• For the general
population, there will
be 'uncertainty' reflects the difference
between the
subjects under trial and
the large population.
• 95% confidence
intervals.

Uncertainty

• One way to think
about 95% CI's is that if
you conduct 100 such
similar studies, 95
of them would contain
the efficacy value.
• FDA's threshold:
efficacy no less than
50% & lower limit of
CI cannot be lower than
30%
• Fortunately, all the
major vaccines
surpassed that.

Uncertainty

• The last thing to note
about CI's is that if there's
a large overlap between
two CI's, then their
difference is not
statistically significant.
• In case of vaccines, it
means that the point
estimates of the efficacy
values might be different,
but if the CI's overlap, their
efficacies are not really
distinguishable.
• There are other factors as
well.

How do vaccines
compare?
• It is very difficult to compare vaccines.
• Vaccines were tested on different groups of
people, during different stages of pandemic.
• They were also measured in different ways –
e.g., J&J 28 days after a single dose, while
Moderna 14 days after a second dose.
• All these vaccines have a high efficacy against
hospitalization & death.
Image from Vox video

A clinical trial is not the final destination, but just a
start.

Effectiveness

Researchers follow the effects of vaccine on the
large popoulation for a long time.
Then, the quantity to look at is called
"effectiveness" - the relative reduction of risk in 'real
world', millions or billions of people.
Early studies show that the vaccines are also quite
effective.

Final remark

"A tale of personal
perseverance"
• Katalin Karikó was dismissed, ignored,
unable to get grants and
demoted. Had a cancer scare &
her husband was stuck in Hungary
sorting out visa issues.
• For three decades, she refused to
quit.
• Ask yourselves, why did it have to be
this way, and how many Katalin
Karikos have quit?
Damian Garde, “The Story of MRNA: How a Once-Dismissed Idea
Became a Leading Technology in the COVID Vaccine Race”
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Questions

The Role of Open Access in COVID-19 Vaccine Research
Angie Ohler, Associate Dean for Content and Digital Initiatives

Open Access
• What
• Why

Community Response

Overview

• Open Science
• Controversy

Future Directions
• Public Discourse
• Cultural Shifts

Open Access

What is Open Access?

OPEN = IMPACT
• Open Access Publishing
• Open access (OA) refers to freely available, digital, online information. Open access
scholarly literature is free of charge and often carries less restrictive copyright and
licensing barriers than traditionally published works, for both the users and the
authors.
• While OA is a newer form of scholarly publishing, many OA journals comply with
well-established peer-review processes and maintain high publishing standards.
• Digital Repositories like ScholarWorks@UARK
• Funding agencies are getting serious about compliance, and that means publicly
funded research must be made available OA
•

Higher visibility for University of Arkansas
authored works, with higher citation rates
and greater impact in the field and beyond.

Why Open
Access?

Publishing with established journals and
presses using trusted peer review
processes.
Opportunities to establish a strong early
career publication record for tenure track
faculty and student authors.
Helps those authors in disciplines who do
not otherwise have grant funding to pay for
publication fees.

Community
Response
to the
Pandemic

Open
Science
•

•

•

•

Public outcry from the
scientific and research
community
Taxpayer funded research
should be freely available
Data sharing and open
peer review
Full access to all research
and publication

Controversy

•
•
•
•

Quantity versus quality
Other models for peer
review
The Lancet retraction
bioRxiv preprint server
retraction

Future Directions

Public
Discourse
•
•

Scholarly Publication in
Historical Context
Societal Impact

Cultural Shifts
•
•

Is this a permanent
change?
Should it be?

•
•
•

FAQ for
Open
Access
Publishing
Fund

•

•
•

•

When will the program begin? July 1, 2021
Is this a one time ask? Yes, this is a pilot program, and we will
be assessing it for continuing.
Is there a plan for dedicated funding? Most research-intensive
universities have had open access grant programs for a long
time. These programs are typically centered within academic
libraries and are funded every year by a combination of funding
from partners across campus.
Will there be limits on the number of asks, the total amount of
requests, the frequency of asks, etc.? We will limit the
requests per author to one per year to make sure the funding
covers as many authors as possible.
Open to students? Yes, open to all institutional authors.
Are there caps on the grant amount? Open access grant funds
at large universities typically cover between $1500 to $3000 per
book or journal article funding request. We will cover up to $2000.
How will the funding be managed? As with other research
institutions, the Libraries will administer the open access funds
and the program will have clearly defined rules as to who is
eligible, what publications are covered, and guidelines for
applying. These will be posted on the Office of Scholarly
Communications page.

Questions?

